ライフサイエンスコーパス: counterpulsation

1 ated with substantial mortality despite IABP counterpulsation.

2 to vasopressors or intra-aortic balloon pump counterpulsation.

3 vasopressor agents and intra-aortic balloon counterpulsation.

4 ) requiring intra-aortic balloon pump (IABP) counterpulsation.

5 cluding thrombolysis and intraaortic balloon counterpulsation.

6 support devices such as intraaortic balloon counterpulsation (7.7%), left ventricular assist device

7 ysis (63% of patients), intra-aortic balloon counterpulsation (86%), and subsequent revascularization

8 data from the first large registry of aortic counterpulsation, a computerized database that incorpora

9 Patients were given 35 h of active counterpulsation (active CP) or inactive counterpulsatio

10 prophylactic intraaortic balloon pump (IABP) counterpulsation after primary percutaneous transluminal

11 atment strategies using intra-aortic balloon counterpulsation and emergency revascularization by perc

12 ity, stabilization with intra-aortic balloon counterpulsation and thrombolysis followed by transfer t

13 early angiography, intra-aortic balloon pump counterpulsation, and early revascularization with PCI o

14 cal ventilatory support, intraaortic balloon counterpulsation, and hemodialysis or ultrafiltration.

15 663 consecutive patients treated with aortic counterpulsation at 250 medical centers worldwide; 5,495

16 Intra-aortic balloon counterpulsation augmentation performed after reperfusio

17 oup, 301 patients) or no intraaortic balloon counterpulsation (control group, 299 patients).

18 sation for 68 hrs or no intra-aortic balloon counterpulsation (control).

19 The use of intraaortic balloon counterpulsation did not significantly reduce 30-day mor

20 o assess the effects of intra-aortic balloon counterpulsation during sepsis with increasing risk of d

21 Enhanced external counterpulsation (EECP) has been shown to reduce angina

22 y assessed the benefits of enhanced external counterpulsation (EECP) in the treatment of patients wit

23 Enhanced external counterpulsation (EECP) is a noninvasive, pneumatic tech

24 s to examine the effect of enhanced external counterpulsation (EECP) on endothelial function.

25 anti-ischemic benefits of enhanced external counterpulsation (EECP) remain unknown.

26 ent evidence suggests that enhanced external counterpulsation (EECP) therapy may improve symptoms and

27 ess safety and efficacy of enhanced external counterpulsation (EECP).

28 Enhanced external counterpulsation enhances peripheral endothelial functio

29 n randomized to receive intra-aortic balloon counterpulsation for 68 hrs or no intra-aortic balloon c

30 ower doses of bacteria, intra-aortic balloon counterpulsation had no significant effects on survival

31 Intra-aortic balloon counterpulsation (IABC) can improve post-myocardial infa

32 Intra-aortic balloon counterpulsation (IABC) is an adjunct to revascularizati

33 myocardial infarction to intraaortic balloon counterpulsation (IABP group, 301 patients) or no intraa

34 and outcomes with early intraaortic balloon counterpulsation (IABP) in patients presenting with card

35 c therapy (TT) and intra-aortic balloon pump counterpulsation (IABP) on in-hospital mortality rates o

36 s between the number of intra-aortic balloon counterpulsation (IABP) procedures performed at a given

37 data on indications for intra-aortic balloon counterpulsation (IABP) use, patient demographics, conco

38 ial benefit of combining intraaortic balloon counterpulsation (IABP) with thrombolysis for acute myoc

39 s, ventilatory support, intra-aortic balloon counterpulsation (IABP), percutaneous transluminal coron

40 highest bacterial dose, intra-aortic balloon counterpulsation improved survival time (23.4 +/- 10 hrs

41 Enhanced external counterpulsation improves symptoms and exercise toleranc

42 (Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure) study asse

43 le ventricle (SMV) was configured to produce counterpulsation in the thoracic aorta similar to that o

44 mber of alternatives to intra-aortic balloon counterpulsation in the treatment of anticipated and est

45 logical benefits achieved by the use of IABP counterpulsation in these situations, all the recent tri

46 ive counterpulsation (active CP) or inactive counterpulsation (inactive CP) over a four- to seven-wee

47 Enhanced external counterpulsation is a viable treatment option for select

48 nternational guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment

49 Intra-aortic balloon counterpulsation is employed in patients with impaired l

50 Enhanced external counterpulsation led to symptomatic improvement (>/=1 Ca

51 ion technique, and operator experience, IABP counterpulsation may be successfully employed for a wide

52 no pLVAD support (intra-aortic balloon pump counterpulsation, n = 6; no support, n = 7).

53 ter studies, the use of intra-aortic balloon counterpulsation, percutaneous ventricular assist device

54 rs, iron chelation, and intra-aortic balloon counterpulsation, perhaps should be retired.

55 ty included preoperative intraaortic balloon counterpulsation, preoperative serum bilirubin of >1.0 m

56 th a low cardiac index, intra-aortic balloon counterpulsation prolongs survival time and lowers vasop

57 Enhanced external counterpulsation reduced angina symptoms and extended ti

58 Enhanced external counterpulsation reduces angina and extends time to exer

59 cardial revascularization, enhanced external counterpulsation, spinal cord stimulation, or sympathect

60 The technique of counterpulsation, studied for almost one-half century no

61 h and broadened indications for intra-aortic counterpulsation, the current indications, associated co

62 ilable devices-the intra-aortic balloon pump counterpulsation, the Impella system, the TandemHeart, a

63 ization and use of intra-aortic balloon pump counterpulsation therapy, the prognosis of patients with

64 cal usage of intraaortic balloon pump (IABP) counterpulsation, there is a paucity of randomized trial

65 ulticenter, randomized controlled trial, the Counterpulsation to Reduce Infarct Size Pre-PCI Acute My

66 ese beneficial effects, intra-aortic balloon counterpulsation was associated with an increase in bloo

67 However, although the concept of external counterpulsation was introduced almost four decades ago,

68 ovascular support using intra-aortic balloon counterpulsation was investigated in a hypodynamic, mech

69 Intraaortic balloon counterpulsation was performed in 86 percent of the pati